Neurocrine Biosciences (NBIX) Price to Book (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Price to Book for 17 consecutive years, with 4.64 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book changed 0.38% year-over-year to 4.64; the trailing twelve-month figure through Jun 2026 stood at 4.64 (changed 0.38% YoY), and the FY2025 full-year result was 4.36, down 16.7% from the prior year.
• Price to Book grew to 4.64 in Q2 2026 per NBIX's latest filing, from 3.89 in the prior quarter.
• Across five years, Price to Book topped out at 6.75 in Q4 2022 and bottomed at 3.89 in Q1 2026.
• Historically, Price to Book has averaged 5.33 across 5 years, with a median of 5.38 in 2023.
• The sharpest annual moves came in 2022 and 2025: Price to Book advanced 14.73% in 2022, then slipped 25.74% in 2025.
• Over 5 years, Price to Book stood at 6.75 in 2022, then decreased by 13.67% to 5.83 in 2023, then fell by 10.08% to 5.24 in 2024, then decreased by 16.7% to 4.36 in 2025, then grew by 6.23% to 4.64 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 4.64, 3.89, and 4.36 for Q2 2026, Q1 2026, and Q4 2025 respectively.